• Management
  • Board of Directors
  • Advisors
  • Robert Davidson

    CEO and Chairman of the Board of Directors

    Edward Maliski, PhD

    President and Chief Science Officer

    Jessica Rousset

    Chief Operating Officer

    Mark Udell

    Chief Financial Officer

    Vered Gigi, PhD

    VP of Strategy and Business Development

    Steven Ruhl

    VP of Manufacturing

    CLOSE X

    Robert Davidson

    Robert Davidson is CURE’s CEO and Chairman of the Board of Directors. Prior to his role at CURE Pharmaceutical, Robert Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio Delivery Technologies Inc., and has served on multiple corporate boards. Mr. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film sold in major drug store chains. Mr. Davidson received his B.S. degree with a concentration in Biological Life Sciences. He has a Masters Certificate in Applied Project Management from Villanova University, Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Davidson also completed his Post Graduate Studies at the University of Cambridge with letter of commendation.

    CLOSE X

    Edward Maliski, PhD

    Dr. Edward Maliski is CURE’s President and Chief Science Office. Mailski is an accomplished research scientist with 30 years of experience in the development of pharmaceutical and biotechnology products. As an executive leader and strategist, Maliski contributed his expertise in project management and chemical research to facilitate the transfer of new discoveries into pharmaceutical products for the Sterling Winthrop Research Institute, Glaxo Research Institute, Merck & Co., and Amgen Inc. Additionally, Dr. Maliski has worked with several successful start-up companies.

    CLOSE X

    Jessica Rousset

    Jessica Rousset is CURE’s Chief Operating Officer. Mrs. Rousset oversees operations and drives corporate strategy and growth. She is a seasoned business development and commercialization leader, expert in bridging corporate, academic and governmental interests toward the common goal of improving patient’s lives. She brings more than fifteen years of experience fostering innovation in large organizations and advising start-ups to bring novel healthcare solutions to market and into clinical use. Mrs. Rousset previously served as Head of Innovation at Children’s Hospital Los Angeles, where over a ten year period, she helped launch both therapeutic and medical device companies and founded and operated a national pediatric technology accelerator. Prior to that, Mrs. Rousset held positions at The Scripps Research Institute and GlaxoSmithkline Biologicals in laboratory, clinical research and business development roles. She trained as a biochemical engineer at the Institut National des Sciences Appliquées in Lyon, France.

    CLOSE X

    Mark Udell

    Mark Udell is CURE’s Chief Financial Officer, Treasurer and Secretary. As CFO, Mr. Udell is responsible for all strategic tactical matters as they relate to budget management, cost benefit analysis, forecasting need, securing of new funding and overseeing the management and coordination of all fiscal reporting activities for the organization. He is a Certified Public Accountant with over 17 years of experience in finance and accounting. Prior to joining CURE Pharmaceutical in 2011, Mr. Udell served as InnoZen, Inc.’s Chief Accounting Officer and Controller and was responsible for establishing, monitoring and enforcing policies and procedures for the company as well as conducting audits and working with external auditors. While working at CURE and InnoZen, Inc., Mr. Udell gained valuable knowledge in the drug delivery industry and is a key contributor in the development and commercialization of various drug delivery technologies. He has also held the position as Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. Mr. Udell received his B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

    CLOSE X

    Vered Gigi, PhD

    Dr. Vered Gigi is CURE’s VP of Strategy and Business Development (BD). As VP of strategy and BD, Dr. Gigi is responsible for the corporate development by identifying and shaping CURE’s strategy both organically and inorganically to deliver sustained growth and diversified revenue. She is also responsible for building and maintaining relationships with the pharmaceutical companies, academia and other collaborators. Together with the office of the COO, her charter is to drive operational excellence and competitiveness. Prior to joining CURE, Dr. Gigi was a Project Leader with the Boston Consulting Group. During her tenure, she led and supported a variety of projects at global biopharma and medtech companies with a focus on corporate and network strategy, operations, marketing and post-merger integration initiatives. Dr. Gigi holds a PhD in Immunology from the University of Pennsylvania and a BSc. in Bio-Medical sciences from Tel-Aviv University in Israel. During her years in academia she investigated immunotherapy, stem cell and DNA repair mechanisms.

    CLOSE X

    Steven Ruhl

    Steven Ruhl is CURE’s VP of Manufacturing, overseeing all process development and manufacturing operations. He is a seasoned leader for drug substance and drug products process development, production facility design, process equipment, construction and CGMP management.  He has a proven track record with building and developing high performing teams to deliver commercial supply and process solutions that meet regulatory requirements. Mr. Ruhl brings more than 35 years of experience leading technical teams.  Most recently he served 11 years at Amgen Thousand Oaks in multiple process development roles. As Process Development Director of Generation Technologies he led the introduction and commissioning of a next generation isolated drug product robotic filler.  Prior to that he served 4 years at Amgen Technologies Ireland as Process Development Site and Tech Transfer Program Lead for multiple Amgen Commercial products where he co-led a $350M capital expansion of an Amgen acquired Pfizer site to expand site capabilities to manufacture, package and cold store finished drug product.  Steven entered Amgen in 2007 as Commercial Drug Product Executive Director responsible for global support and lifecycle management of Amgen’s commercial products. Previously, Steven held management positions at CancerVax, Certified Facilities, IDEC Pharmaceuticals, Xoma and Celtrix Pharmaceuticals.  He served IDEC during the time of two firsts for monoclonal antibody therapies with development and launch of Rituxan® and co-led the CMC development for Zevalin® radioimmune conjugate. He trained as microbiologist and chemist at Brigham Young University.

  • William Yuan

    Director

    William Yuan was most recently Chairman and CEO of Fortress Hill Holdings, an Asian-based investment banking firm. With 23 years in global finance experience, he has served as a key strategist and advisor to international institutions. U.S. companies advised by Mr. Yuan include Amgen Corp., Biogen, GE Capital, Warner Brothers Studios, and Fox News. He has also guided such leading Asian institutions as Sina.com, Shanghai Petrochemicals, Jinlia Pharmaceutical and Tsingtao Beer Corp. In 1995, Mr. Yuan led Merrill Lynch Asset Management Asia, and managed one of the largest pension/retirement funds in the world, with a $488 billion portfolio under his leadership. Simultaneously, he was chairman and portfolio manager of the $1.2 billion AmerAsia Hedge Fund. In 1993, he was the founder and managing director of the Corporate Institutional Services Group at Merrill Lynch Asset Management. Prior to that, Mr. Yuan served as a senior-vice president and co-manager at Morgan Stanley Smith Barney’s Portfolio Management Corporation with dual functions as co-head of the Capital Markets Derivative team, and Chairman of the Technology Investment Management and Executive Policy Committee. He began his finance career at Goldman Sachs in 1983 as an investment banker in Mergers & Acquisitions. Mr. Yuan is a member of the International Who’s Who of Finance, Technology, Media and Telecom. Mr. Yuan holds a Bachelor of Science degree in Economics from Cornell University and attended Harvard University’s John F. Kennedy School as a Mason Fellow.

    Charles Berman

    Director

    Formerly a shareholder at Greenberg Traurig LLP, and partner at other leading law firms including Merchant and Gould, Charles Berman has focused his practice in patent work for more than 40 years. His clients include both major corporations and smaller companies, which he represents within the U.S. and internationally. He has a degree in electrical engineering and a law degree from the University of Witwatersrand in Johannesburg, where he also started his legal career, concentrating in patent work. In 1978 Berman joined Lyon & Lyon’s Los Angeles office as an associate, and he has remained in the U.S. ever since. HeHe is admitted to practice before the United States Supreme Court, the US Patent and Trademark Offices, the US District Court, Central District of California. From 1996-2000, he served as president, secretary and treasurer of the Los Angeles Intellectual Property Law Association (“LAIPLA”), and has represented LAIPLA and the California State Bar Intellectual Property Section before the U.S. Bar/European Patent Office- Liaison Council and the U.S. Bar/Japanese Patent Office- Liaison Council since 1990. Berman also has been a member of the Editorial Board of Managing Intellectual Property magazine since 1992. A board member of the American Intellectual Property Association form 1995 to 1998, he was a founding fellow of the AIPLA.

    Alan Einstein, MD

    Director

    Dr. Alan Einstein, grandson to famed Albert Einstein, has been practicing medicine since 1996. His educational history includes a Bachelors of Science undergraduate degree in Physical Chemistry from The University of Florida. Subsequently, he earned his medical degree from The College of Osteopathic Medicine and Surgery in Des Moines, Iowa, in 1992. Subsequently, Dr. Einstein completed his Internship and Residency training at The Johns Hopkins University School of Medicine/Sinai Hospital program in Internal Medicine, in Baltimore, MD in 1995, where he was recognized as, “The Outstanding Senior Resident of the Year.” Dr. Einstein is also involved in medical research utilizing Umbilical Cord Blood stem cells, with a particular interest in Parkinson’s disease. Dr. Einstein also assisted Senator David Shafer in the writing and passage of Georgia’s first and only Cord Blood stem cell bill. Furthermore, in July 2006, Georgia’s Governor Sonny Perdue appointed Dr. Einstein to the, “Commission for Newborn Umbilical Cord Blood Research and Medical Treatment.” He emphasizes health and preventative care to allow individuals to achieve their maximum potential. He has numerous areas of medical expertise including cardiovascular diseases, diabetes, thyroid and hormone metabolism disorders. He emphasizes returning adults to a normal hormonal state, yet via a more natural route. Furthermore, Dr. Einstein is a thought leader in the area of metabolic syndrome and its role in weight gain and overall health and longevity. He has presented to his medical peers at numerous medical institutions and conferences around the country, and has been featured on Video Health Magazine and Diabetes News Stand.Dr. Einstein prides himself in individualized and unrushed medical care. He takes detailed histories and performs thorough physical examinations while paying attention to detail.

  • Richard Serbin

    Mr. Richard S. Serbin is a global strategy advisor and entrepreneur with credentials both in pharmacy and law, complemented by more than 40 years of service as an FDA regulatory attorney and consultant and patent attorney in the healthcare industry. Mr. Serbin is an expert in licensing medical extracts, compounds, and technologies. He is a pharmacist and patent attorney with more than 40 years of experience in the pharmaceutical industry and the investment community. Mr. Serbin spent a large portion of his career focusing on international markets and clients. He also serves as COO of the Gorlin Companies, a family office focused on healthcare technologies, and is COO of Sapir Pharmaceuticals, an early stage pharmaceutical company with offices in the US and France.  He has held senior positions at Schering-Plough Corporation, Revlon Corporation and Johnson & Johnson Corporation, and has been the founder or co-founder of over 10 heathcare technology and/or healthcare service organizations.  He sits on the Boards of several healthcare companies and on the Advisory Board of the Swedish American Life Science Summit.

    Michael Neely, MD

    Dr. Neely is the director of the University of Southern California Laboratory of Applied Pharmacokinetics, which has been at the forefront of nonparametric population pharmacokinetic modeling techniques and dose optimization for individual patients for over 35 years. He is an Associate Professor of Pediatrics, Clinical Scholar at the University of Southern California (USC) and at Children’s Hospital Los Angeles. His research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients. He has a Master of Science degree in Clinical and Biomedical Investigations from USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling. He is a member of the United States Food and Drug Administration Anti-­infective Drug Advisory Committee and board certified in pediatrics, pediatric infectious diseases and a Fellow of the American College of Clinical Pharmacology. He completed a four-year NIH career development award, and is the Principle Investigator for two R01 awards from the NIH totaling over 6 million dollars over 5 years to develop and apply pharmacometric techniques to anti-infective therapy in populations and individual patients. Dr. Neely has over 50 publications in peer-reviewed journals, and is invited to give talks and workshops on dose individualization and optimization worldwide.

    Gene Salkind, MD

    Dr. Salkind is board certified in neurological surgery by the American Board of Neurological Surgery and completed various residencies, fellowships and postgraduate training at Abington Memorial hospital, The Graduate Hospital, Veteran’s Administration Hospital,  Pennsylvania Hospital, Children’s Hospital of Philadelphia, and the Hospital of the University of Pennsylvania. He received his Medical Degree from Temple University School of Medicine and his Bachelor of Arts from the University of Pennsylvania.  He has had numerous faculty, hospital and administrative appointments at virtually every major hospital in the northeastern Philadelphia and surrounding areas. As a prolific pharmaceutical investor, some of Dr. Salkind’s previous successful investments include Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250/share, and Centocor, one of the nation’s largest biotechnology companies, which was acquired by Johnson & Johnson for $4.9 billion in stock. Dr. Salkind currently sits on the board of DermTech, a private company based in San Diego that has become the global leader in non-invasive dermatological molecular diagnostics.

    Tracy Ryan

    Mrs. Ryan, founder of Canna Kids, a CA Cooperative Corporation that specializes in the creation of lab tested and Ph.D. scientist extracted cannabis oils, after realizing success using cannabinoid therapy on her own 8 ½-month-old infant who was diagnosed with a rare brain tumor. After establishing CannaKids in mid-2014, she partnered with scientists and pediatric physicians to formulate her own cannabinoid product line that was later released into the California market in 2015. She has gained educating the mass public on the power of the cannabis plant, as continue work in the pharmaceutical cannabis sector. She has vast, first-hand knowledge on the medicinal powers of cannabis in treating her own daughters disease and has worked on a global scale helping families who seek education and treatment options, guiding many patients to a better quality of life.

CURE PHARMACEUTICAL
Corporate HQ, Receiving, & Manufacturing
1620 Beacon Place
Oxnard, CA 93033
Phone: 1-805-824-0410
Fax: 1-805-487-7163

We’re growing fast. Come join us!

We seek entrepreneurial employees that will build upon and execute CURE’s vision for moving drug delivery into the future, espousing our core values: Integrity, Humanity and Intelligence.

We are Principled throughout our actions, communications, decisions, methods, and outcomes.

We embrace our Humanity by cultivating diversity and being compassionate to the needs of others.

We nurture our Intelligence by creating together and trusting our intuition.

For employment opportunity inquiries:
[email protected]